semaglutide and excedrin Novo Nordisk's shortage officially concludes in the US, spelling major threat for weight loss drug compounders Microdosing Semaglutide: Weight Loss Plus

Competition is perhaps the single most important dynamic to understand when evaluating companies.

GLP-1 Medications: Rethinking My Stance + How to Support Yourself While Using Them Ill admit it: I was extremely biased against GLP-1 medications when I first heard about them

The real disruption won't announce itself

The tennis star says shes lost 31 pounds on a weight-loss drug.

reducing reliance on costly imports." Key findings: With 98 GLP-1 drugs in trials, patent expiry in 2026 enabling biosimilars, and a projected $150B market by 2035, China could challenge Western dominancedespite regulatory hurdles and US tariffs